Cardiology/Vascular Diseases | Approved Drugs | CANADA

Correvio Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp

Lead Product(s): Vernakalant Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Advanz Pharma

Deal Size: $76.0 million Upfront Cash: $76.0 million

Deal Type: Acquisition May 27, 2020

Details:

Advanz Pharma believes that Correvio's niche portfolio, consisting of an established brand, and two growing, patent-protected brands, plus a pipeline of potential product launches, are highly complementary to its current priorities and future focus.

Correvio Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Correvio Partners with Hong Kong Teson Pharma Limited

Lead Product(s): Tirofiban Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Hong Kong Teson Pharma

Deal Size: $3.5 million Upfront Cash: $3.0 million

Deal Type: Agreement March 10, 2020

Details:

The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.

Dalton Pharma Services

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Dalton Expands Cannabinoids Capabilities

Lead Product(s): Cannabidiol

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Health Canada

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 15, 2020

Details:

Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.

Find

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in CANADA

Canada

Product Type

Companies

Correvio Pharma

Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp

Correvio Pharma

Correvio Partners with Hong Kong Teson Pharma Limited

Dalton Pharma Services

Dalton Expands Cannabinoids Capabilities